Open aneurysmorraphy following branched and fenestrated endovascular repair of complex thoracic aneurysms.

IF 3.9 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE
Florent Porez, Dominique Fabre, Blandine Maurel, Antoine Gaudin, Alessandro Costanzo, Mark R Tyrrell, Thomas Le Houérou, Stéphan Haulon
{"title":"Open aneurysmorraphy following branched and fenestrated endovascular repair of complex thoracic aneurysms.","authors":"Florent Porez, Dominique Fabre, Blandine Maurel, Antoine Gaudin, Alessandro Costanzo, Mark R Tyrrell, Thomas Le Houérou, Stéphan Haulon","doi":"10.1016/j.jvs.2024.09.033","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>We present a review of our hybrid management (endovascular + open surgery) of large thoracic aortic aneurysms (>80 mm). The strategy comprises a primary endovascular repair using thoracic endovascular aortic repair (TEVAR), and/or fenestrated and branched endografts (FBEVAR), followed by open thoracotomy and aneurysmorraphy, specifically without the need for aortic cross-clamping.</p><p><strong>Methods: </strong>We performed a retrospective review of all patients who had undergone aneurysmorraphy via thoracotomy following TEVAR and FBEVAR in two high-volume aortic centers between December 2017 and March 2024. We performed aneurysmorraphy in two clinical situations: (1) in the setting of a planned staged treatment, shortly after TEVAR or FBEVAR in young patients with aneurysm diameter >100 mm; and (2) as a secondary intervention during follow-up for patients with persistent sac enlargement and aneurysm diameters >80 mm. The primary end points were 30-day survival and aneurysm-related mortality during follow-up. Secondary endpoints were sac size evolution, perioperative and postoperative complications, freedom from further reintervention, and late aortic complications.</p><p><strong>Results: </strong>Twelve patients underwent aneurysmorraphy following TEVAR and/or FBEVAR during the study period. Mean patient age was 60 ± 12 years, and the mean sac diameter before thoracotomy was 101 ± 25 mm. Endovascular embolization of intercostal arteries prior to aneurysmorraphy was performed in four patients. The 30-day survival rate was 100%. During the mean follow up period of 21 months, two patients died-one of COVID and another of intra-cerebral hemorrhage. No aneurysm-related mortality occurred, and sac regression was achieved in all patients except one experiencing aortic growth below the aneurysmorraphy.</p><p><strong>Conclusions: </strong>This study demonstrates that thoracic aneurysmorraphy performed after TEVAR and FBEVAR for complex thoracic aneurysms is a safe and effective technique. This procedure allows the eradication of endoleaks and an immediate sac volume reduction, which prevents aorta-bronchial or esophageal fistulation and secures the endovascular repair; the reduction of the aneurysm mass effect restores normal lung parenchyma expansion. This hybrid management strategy drastically reduces the morbidity associated with standard open surgery performed for thoracic endograft explantation.</p>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Vascular Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jvs.2024.09.033","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: We present a review of our hybrid management (endovascular + open surgery) of large thoracic aortic aneurysms (>80 mm). The strategy comprises a primary endovascular repair using thoracic endovascular aortic repair (TEVAR), and/or fenestrated and branched endografts (FBEVAR), followed by open thoracotomy and aneurysmorraphy, specifically without the need for aortic cross-clamping.

Methods: We performed a retrospective review of all patients who had undergone aneurysmorraphy via thoracotomy following TEVAR and FBEVAR in two high-volume aortic centers between December 2017 and March 2024. We performed aneurysmorraphy in two clinical situations: (1) in the setting of a planned staged treatment, shortly after TEVAR or FBEVAR in young patients with aneurysm diameter >100 mm; and (2) as a secondary intervention during follow-up for patients with persistent sac enlargement and aneurysm diameters >80 mm. The primary end points were 30-day survival and aneurysm-related mortality during follow-up. Secondary endpoints were sac size evolution, perioperative and postoperative complications, freedom from further reintervention, and late aortic complications.

Results: Twelve patients underwent aneurysmorraphy following TEVAR and/or FBEVAR during the study period. Mean patient age was 60 ± 12 years, and the mean sac diameter before thoracotomy was 101 ± 25 mm. Endovascular embolization of intercostal arteries prior to aneurysmorraphy was performed in four patients. The 30-day survival rate was 100%. During the mean follow up period of 21 months, two patients died-one of COVID and another of intra-cerebral hemorrhage. No aneurysm-related mortality occurred, and sac regression was achieved in all patients except one experiencing aortic growth below the aneurysmorraphy.

Conclusions: This study demonstrates that thoracic aneurysmorraphy performed after TEVAR and FBEVAR for complex thoracic aneurysms is a safe and effective technique. This procedure allows the eradication of endoleaks and an immediate sac volume reduction, which prevents aorta-bronchial or esophageal fistulation and secures the endovascular repair; the reduction of the aneurysm mass effect restores normal lung parenchyma expansion. This hybrid management strategy drastically reduces the morbidity associated with standard open surgery performed for thoracic endograft explantation.

复杂胸腔动脉瘤的分支和瘘管血管内修复术后的开放式动脉瘤造影术。
目的:我们对胸主动脉瘤(大于 80 毫米)的混合治疗(血管内手术+开放手术)进行了回顾。该策略包括使用胸腔内血管主动脉修复术(TEVAR)和/或穿孔和分支内皮移植术(FBEVAR)进行初级血管内修复,然后进行开胸手术和动脉瘤造影术,特别是无需进行主动脉交叉夹闭:我们对 2017 年 12 月至 2024 年 3 月期间在两个大容量主动脉中心接受 TEVAR 和 FBEVAR 后通过开胸手术进行动脉瘤造影术的所有患者进行了回顾性回顾。我们在两种临床情况下进行了动脉瘤造影术:1)在计划分期治疗的情况下,在动脉瘤直径大于 100mm 的年轻患者接受 TEVAR 或 FBEVAR 后不久;以及 2)在随访期间,对囊持续增大且动脉瘤直径大于 80mm 的患者进行二次干预。主要终点是随访期间的 30 天存活率和动脉瘤相关死亡率。次要终点是瘤囊大小变化、围手术期和术后并发症、免于再次介入和晚期主动脉并发症:研究期间,12 名患者在接受 TEVAR 和/或 FBEVAR 术后接受了动脉瘤造影术。患者平均年龄为 60 +/- 12 岁,开胸手术前的平均囊直径为 101 +/- 25 毫米。4名患者在动脉瘤手术前进行了肋间动脉血管内栓塞术。30 天存活率为 100%。在平均 21 个月的随访期间,有两名患者死亡,其中一名死于 COVID,另一名死于脑内出血。除了一名主动脉瘤生长低于动脉瘤造影术的患者外,所有患者都实现了囊消退:本研究表明,在 TEVAR 和 FBEVAR 治疗复杂胸腔动脉瘤后进行胸腔动脉瘤造影术是一种安全有效的技术。该手术可消除内漏并立即缩小囊体积,从而防止主动脉-支气管或食管瘘,并确保血管内修复术的安全;动脉瘤肿块的缩小效应可恢复正常的肺实质扩张。这种混合管理策略大大降低了胸腔内移植物剥离标准开放手术的发病率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.70
自引率
18.60%
发文量
1469
审稿时长
54 days
期刊介绍: Journal of Vascular Surgery ® aims to be the premier international journal of medical, endovascular and surgical care of vascular diseases. It is dedicated to the science and art of vascular surgery and aims to improve the management of patients with vascular diseases by publishing relevant papers that report important medical advances, test new hypotheses, and address current controversies. To acheive this goal, the Journal will publish original clinical and laboratory studies, and reports and papers that comment on the social, economic, ethical, legal, and political factors, which relate to these aims. As the official publication of The Society for Vascular Surgery, the Journal will publish, after peer review, selected papers presented at the annual meeting of this organization and affiliated vascular societies, as well as original articles from members and non-members.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信